University of North Carolina at Chapel Hill
Date: November 2015
Purpose: to further knowledge and share experience with improving access, quality, and use of family planning services
Amount: $5,948,233
Term: 55
Topic: Family Planning
Regions Served: GLOBAL|AFRICA|NORTH AMERICA
Program: Global Development
Grantee Location: Chapel Hill, North Carolina
Grantee Website: http://www.unc.edu
GRANTEE: BILL GATES
https://waterinstitute.unc.edu/files/2015/12/clts-gates-ghana-2015.pdf
Date: October 2016
Purpose: to support the study on how receipt of cash transfers to young girls and women influence their sexual behavior and financial decisions
Amount: $1,790,407
Term: 46
Topic: HIV
Program: Global Health
Grantee Location: Chapel Hill, North Carolina
Grantee Website: http://www.unc.edu
ARE YOU READING THIS!!!
LOOK AT PURPOSE
PROSITITUTION STUDY
SAUCE
https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2016/10/OPP1158402
University of North Carolina at Chapel Hill
Date: November 2016
Purpose: to inform future family planning investments that are intended to lead to long-term increases in urban women’s, couples’, and adolescents’ modern family planning adoption and use
Amount: $1,754,176
Term: 44
Topic: Family Planning
Regions Served: GLOBAL|AFRICA|NORTH AMERICA
Program: Global Development
Grantee Location: Chapel Hill, North Carolina
Grantee Website: http://www.unc.edu
https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2016/11/OPP1161858
UNC awarded $2.91 million to create new ultra-long-acting HIV drug delivery implant
Led by J. Victor Garcia, PhD, biomedical researchers have begun a three-year project funded by the Bill & Melinda Gates Foundation to develop and implement an effective ultra-long-acting antiviral delivery system to combat the spread of HIV.
UNC awarded $2.91 million to create new ultra-long-acting HIV drug delivery implant
click to enlarge
J. Victor Garcia, PhD
November 6, 2019
HIV clinical trials have shown that the protective efficacy of daily antiretroviral drugs for prevention of HIV transmission correlates with adherence – whether an uninfected person takes the prescribed medication at proper times. But nonadherence is a major roadblock toward decreasing the spread of HIV. One solution to the adherence problem is to make drug delivery less frequent but no less effective.
UNC School of Medicine investigators and colleagues were awarded $2.91 million over three years by the Bill & Melinda Gates Foundation to create an ultra-long-acting formulation based on phase inversion implant technology. The principal investigator is J. Victor Garcia, PhD, professor of medicine at UNC-Chapel Hill.
“We are excited that the Gates Foundation has seen the great potential of ultra-long-acting PrEP formulations and has awarded our multidisciplinary team of researchers funding to further test an ultra-long-acting drug delivery system,” said Garcia, who is a member of the UNC Institute for Global Health and Infectious Diseases and Director of the International Center for the Advancement of Translational Science.
“The injectable implant is composed of three main components – an organic water miscible solvent, a biodegradable polymer, and the drug or drugs that need to be delivered. The formulation results in a syringeable liquid that turns into a solid when injected under the skin and releases drug(s) steadily over time,” said Rahima Benhabbour, PhD, assistant professor in the UNC/NC State Joint Department of Biomedical Engineering and lead developer of the ISFI formulation for this project.
“This ultra-long acting ISFI formulation is simple to prepare, has an initial targeting of 180 days of sustained drug release, and will contain an active pharmaceutical ingredient called EFdA, which has potent anti-HIV activity several orders of magnitude higher than currently approved drugs,” said Martina Kovarova, PhD, associate professor of medicine at UNC and director of the project.
“Our preliminary data demonstrates the feasibility of this approach for EFdA in vitro and in two in vivo models for the integrase inhibitor dolutegravir,” Garcia said. “Thanks to the Gates Foundation investment, we will develop a similar formulation for EFdA, confirm its stability under relevant conditions, demonstrate appropriate release properties in solutions, and demonstrate sustained release in large animal models.”
Along with Drs. Garcia, Kovarova, and Benhabbour, other investigators are Agata Exner, PhD, professor of radiology and biomedical engineering at Case Western Reserve University; Allison Rogala, DVM, assistant professor of pathology and lab medicine at the UNC School of Medicine; Mackenzie Cottrell, PharmD, researcher assistant professor at the UNC Eshelman School of Pharmacy; Michael Hudgens, PhD, professor of biostatistics at the UNC Gillings School of Global Public Health; Katie Mollan, PhD, senior biostatistician at the UNC Center for AIDS Research at the UNC School of Medicine; and Bonnie Shook-Sa, graduate research assistant in biostatistics at the UNC Gillings School of Global Public Health.
This grant supports For All Kind: the Campaign for Carolina, the most ambitious fundraising campaign in the history of the University of North Carolina at Chapel Hill. The campaign is inspired by the Blueprint for Next, the University’s overall strategic plan built on two core strategies: “of the public, for the public,” and “innovation made fundamental.”
Media contact: Mark Derewicz, 984-974-1915
http://news.unchealthcare.org/news/2019/november/unc-awarded-2-91-million-to-create-new-ultra-long-acting-hiv-drug-delivery-implant
UNC receives $14M from Bill Gates' foundation to research childbirth in underdeveloped countries
CHAPEL HILL, N.C. (WTVD) – A team of clinical researchers at UNC-Chapel hill has received $14 million to conduct two studies aimed at improving pregnancy outcomes in the world's poorest countries.
According to a release from the University, the money was awarded by the Bill and Melinda Gates Foundation.
Stay on top of breaking news stories with the ABC11 News App
A team of researchers from the UNC School of Medicine and the UNC Gillings School of Global Public Health will lead the studies.
The release said that the team will be "exploring the role of technology in predicting and addressing key risk factors associated with pregnancy, labor, and delivery" in the world's poorest countries.
"In many parts of the world, the days surrounding childbirth are the riskiest period a mother and her newborn will ever face," said Dr. Jeffrey Stringer, professor of obstetrics & gynecology in the UNC School of Medicine and adjunct professor of epidemiology in the UNC Gillings School of Global Public Health. "These studies will develop resource-appropriate technologies to make that time much safer."
RELATED: Smoking while pregnant doubles risk of baby's sudden death, study finds
Each year, roughly 300,000 women and 3 million babies worldwide die during childbirth or shortly thereafter, according to the World Health Organization.
Local mom donates onesies to UNC's NICU after son's battle
Environmental and structural factors, underlying infectious disease burden, nutritional factors, and underperforming health systems are just some of the major reasons for this.
The first study, known as the Limiting Adverse Birth Outcomes in Resource-Limited Settings, or LABOR study, is said to be focusing on the period of pregnancy between the onset of labor through delivery.
According to the release, the team will evaluate 15,000 women at clinics in three developing countries, including UNC-Chapel Hill's flagship partnership in Zambia. The team will be giving out wearable physiologic sensors to monitor laboring mothers and their fetuses and documenting the outcomes.
"The data produced by this study will allow us to create a new collection of precision medicine tools that can be used in developing countries to help medical providers better manage patients' unique needs and result in healthier mothers and babies" said Michael Kosorok, the W.R. Kenan Jr. Distinguished Professor and chair of biostatistics at the UNC Gillings School.
There will also be a second study, called the Fetal Age Machine Learning Initiative study, or FAMLI.
In this one, an ultrasound device will be sent to areas with limited resources in order to "assess gestational age and other important obstetric information while requiring minimal operator expertise," the release said.
The data from both studies will be made publicly available through the Gates Foundation's Knowledge Integration team and will allow interested groups to access and continue improving maternal-child health.
https://books.google.ch/books?id=ny93DwAAQBAJ&pg=PA254&lpg=PA254&dq=UNIVERSITY+CHAPEL+HILL+BILL+GATES+2017&source=bl&ots=988JKQSkmq&sig=ACfU3U09xuzjDHDA91-X6zhHAFUyGTE_QA&hl=de&sa=X&ved=2ahUKEwiA44fu2vDoAhWMiqQKHU1yCDEQ6AEwEnoECAsQQQ#v=onepage&q=UNIVERSITY%20CHAPEL%20HILL%20BILL%20GATES%202017&f=false
THIS REFERS TO BROKERED SUBJECTS A BOOK. BILL AND MELINDAS NAME SHOW UP IN IT WILD
SAUCE
Brokered Subjects is a bold and timely book that is bound to compel a rethinking of contemporary understandings of gender progress and freedom.” “Bernstein's important book on the so-called new abolitionism not only debunks the myth of human trafficking.
https://www.press.uchicago.edu/ucp/books/book/chicago/B/bo28509142.html
WTF
there>>8831885
notable on top the book involves human trafficking bill gates contributor
>Date: October 2016
>Purpose: to support the study on how receipt of cash transfers to young girls and women influence their sexual behavior and financial decisions
>Amount: $1,790,407
>Term: 46
>Topic: HIV
>Program: Global Health
>Grantee Location: Chapel Hill, North Carolina
>Grantee Website: http://www.unc.edu
very interesting purpose
Purpose: to support the study on how receipt of cash transfers to young girls and women influence their sexual behavior and financial decisions